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Abstract
Purpose The Dementia-Related Quality of Life (DEMQOL) measure and the DEMQOL-Utility Score (DEMQOL-U) are 
validated tools for measuring quality of life (QOL) in people with dementia. What score changes translate to a clinically 
significant impact on patients’ lives was unknown. This study establishes the minimal important differences (MID) for these 
two instruments.
Methods Anchor-based and distribution-based methods were used to estimate the MID scores from patients enrolled in a 
randomised controlled trial. For the anchor-based method, the global QOL (Q29) item from the DEMQOL was chosen as 
the anchor for DEMQOL and both Q29 and EQ-5D for DEMQOL-U. A one category difference in Q29, and a 0.07 point 
difference in EQ-5D score, were used to classify improvement and deterioration, and the MID scores were calculated for 
each category. These results were compared with scores obtained by the distribution-based methods.
Results A total of 490 people with dementia had baseline DEMQOL data, of these 386 had 8-month data, and 344 had 
12-month DEMQOL data. The absolute change in DEMQOL for a combined 1-point increase or decrease in the Q29 anchor 
was 5.2 at 8 months and 6.0 at 12 months. For the DEMQOL-U, the average absolute change at 8 and 12 months was 0.032 
and 0.046 for the Q29 anchor and 0.020 and 0.024 for EQ-5D anchor.
Conclusion We present MID scores for the DEMQOL and DEMQOL-U instruments obtained from a large cohort of patients 
with dementia. An anchored-based estimate of the MID for the DEMQOL is around 5 to 6 points; and 0.02 to 0.05 points 
for the DEMQOL-U. The results of this study can guide clinicians and researchers in the interpretation of these instruments 
comparisons between groups or within groups of people with dementia.
Trial Registration Number and date of registration: ISRCTN17993825 on 11th October 2016.
Keywords People with dementia · DEMQOL · DEMQOL-U · Minimum important difference · Responsiveness
Plain english summary
The Dementia-Related Quality of Life questionnaire is one 
way of measuring the quality of life of people diagnosed 
with dementia. The questionnaire has 29 questions, about 
topics including looking after yourself, health and well-
being and relationships and scores range between 28 and 
112. Higher scores indicate better quality of life. Until now, 
when using this questionnaire for research, we did not know 
what change or difference in scores a person with dementia 
would feel was important and which would cause doctors to 
think about a change in the person’s treatment or care. After 
using statistical techniques to assess this, we estimate that 
people with dementia would feel that a questionnaire score 
change of 5 or 6 points would be helpful and would cause 
their doctors to think about a change in the person’s treat-
ment or care.
This information will help researchers to design future tri-
als (they can work out how many people must be recruited) 
and analyse the results (has the activity or drug had a clini-
cally significant effect on people?).
We also looked at the DEMQOL-Utility score (used by 
health economists to understand if activities or drugs are 
value for money) which ranges from 0.243 to 0.986 and is 
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calculated using the Dementia-Related Quality of Life ques-
tionnaire scores. We found that a 0.02 to 0.05 points increase 
in the DEMQOL-Utility score would indicate that the per-
son being tested was experiencing a clinically significant 
increase in quality of life.
Introduction
Dementia is an umbrella term for a variety of diseases and 
conditions affecting the brain distinguished by a decline in 
memory, language, problem-solving and other thinking skills 
that affect a person’s ability to perform everyday activities. 
There are a number of sub-types of dementia, but the five 
most common are Alzheimer’s disease, vascular dementia, 
dementia with Lewy bodies, frontotemporal dementia and 
mixed dementia. Alzheimer’s is the most common cause of 
dementia [1]. As a person’s age increases, so does the risk 
of them developing dementia [2].
Worldwide, around 50 million people have dementia, 
and there are up to 10 million new cases every year [3]. 
Projections show that there will be 82 million people with 
dementia in 2030 and 152 million in 2050 [3]. Alzheimer’s 
Research UK reports that there are over 850,000 people cur-
rently living with dementia in the UK [4]. It is estimated that 
the number of people with dementia in the UK will rise to 
over one million by 2021 [1].
There is no treatment currently available to cure dementia 
or to alter its progressive course. Numerous new treatments 
are being investigated in various stages of clinical trials [3]. 
However, much can be offered to support and improve the 
lives of people with dementia and their careers and families 
and services are being encouraged to provide post-diagnostic 
treatment and support [5].
Given that we are currently unable to cure people with 
dementia, maintaining or enhancing quality of life (QOL) 
is often an important therapeutic goal [6]. Therefore, accu-
rately measuring QOL is required to both guide clinical deci-
sion making and evaluate the impact of various interventions 
in the population of people with dementia. For this purpose, 
validated instruments have been developed to evaluate QOL 
in patients with dementia including the DEMQOL and 
DEMQOL-U. The DEMQOL is a patient-reported outcome 
measure (PROM) which is designed to enable the assess-
ment of health-related quality of life of people with dementia 
[7]. The DEMQOL-U consists of items from the DEMQOL 
and generates a preference-based single index or score for 
use in economic evaluations [8].
Interpreting the numerical scores on these instruments 
can be challenging for a number of reasons. The scales and 
instruments used may be unfamiliar to many patients and 
clinicians, who may be uncertain of the meaning of the scale 
values and summary scores [9]. It is relatively simple to 
determine the statistical significance of a change in QOL 
but placing the magnitude of these changes in a context that 
is meaningful for patients, health professionals, and other 
stakeholders (pharmaceutical and medical device devel-
opers, insurance payers, regulators, governments) has not 
been so easy. Ascertaining the magnitude of change that 
corresponds to a minimal important difference would help 
to address this problem.
Jaeschke et al. 1989 defined the minimal important dif-
ference, from the patient perspective, as “The smallest dif-
ference in score in the domain of interest which patients per-
ceive as beneficial and which would mandate, in the absence 
of troublesome side effects and excessive cost, a change in 
the patient’s management” [10].
Thus, individual change standards are needed to provide 
meaningful interpretation of treatment effects on QOL and 
to classify patients based on this standard as improved, sta-
ble or declined. Anchor-based and distribution-based meth-
ods can be used for estimating the MID in QOL instruments 
[9, 11, 12]. The aim of this study was to estimate the MID 
for the DEMQOL and DEMQOL-U instruments for com-
parisons between groups or within groups of people with 
dementia in a prospective cohort of people with dementia 
who were recruited as part of an RCT.
Methods
The journeying through dementia trial
The data for this study are provided from the Journeying 
through Dementia (JtD) Trial, a randomised controlled trial 
that recruited participants with early-stage dementia from 
across the UK [13]. In total, 490 participants completed 
baseline data, 480 of these participants were randomised 
1:1 to receive usual care or the JtD programme plus usual 
care. Participants were eligible for the study if they had a 
diagnosis of dementia, a Mini Mental State Examination 
(MMSE) score of 18 or more (indicating that the person 
was in the milder stages of dementia), a good understanding 
of English, and were living in the community (not in resi-
dential or nursing care). The Journeying through Dementia 
programme involved twelve weekly group sessions with two 
trained health practitioners and four individual one-to-one 
sessions with one of those practitioners. The trial ran 28 
groups across 13 sites and those registered for each group 
varied from four to 12. Participants were followed up at eight 
and 12 months, and the primary outcome was DEMQOL at 
eight months post-randomisation.
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Instruments and scoring
The DEMQOL questionnaire contains 29 questions [7]. 
The first 28 items are summed to calculate the DEMQOL 
score and cover 5 domains: daily activities and looking 
after yourself, health and well-being, cognitive functioning, 
social relationships and self-concept. It is completed by the 
person with dementia, in the case of JtD through interview 
in the person’s home. Each item in the DEMQOL is rated 
on a 4-point scale: 1 (a lot), 2 (quite a bit), 3 (a little) and 
4 (not at all). A separate global quality of life item, Q29, 
asks respondents to rate ‘your quality of life overall’ in the 
past week on 4-point scale, which is rated 1 (very good), 
2 (good), 3 (fair) and 4 (poor) (see Online Resource 1 for 
full wording of Q29). Question 29 does not contribute to 
the DEMQOL total score. Six items (including Q29) are 
reverse coded so that for all items, a higher score means bet-
ter health-related quality of life. Responses to the 28 items 
on the DEMQOL are summed to generate a total score on a 
28 to 112 scale, where higher scores indicate better health-
related quality of life.
The DEMQOL-U classification system comprises five 
dimensions (positive emotion, memory, relationships, nega-
tive emotion and loneliness) with four levels of increasing 
impairment associated with each dimension [8]. The scoring 
algorithms for the DEMQOL-U were derived using the time 
trade-off elicitation technique in a UK general population 
sample. The resulting utility scores lie on the zero to one 
quality-adjusted life years (QALY) scale where zero rep-
resents the state dead and one represents the state of full 
health. The utility scores for the DEMQOL-U range from 
0.243 to 0.986.
The EQ-5D-5L (hereinafter referred to as EQ-5D) is a 
health status classification measured over 5 dimensions: 
mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression [14]. Each dimension is assessed by a 
single question on a five-point ordinal scale (e.g. no prob-
lems, slight problems, moderate problems, severe problems, 
unable). The EQ-5D preference-based measure can be cal-
culated by assigning preference weights value sets to the 
raw scores. The EQ-5D preference-based score ranges from 
-0.59 to 1.00 where 1.00 indicates “full health”, 0.00 repre-
sents dead, and a negative score represents a health status 
valued as worse than dead.
Statistical analysis
All statistical analyses were performed in Stata v16 [15]. 
The DEMQOL score was calculated by summing the 
response to the first 28 items when at least half (14 or more) 
of the items were answered, the missing items were imputed 
with the mean of the completed items [16]. The EQ-5D was 
scored using the mapping function developed by van Hout 
et al. [17], no score was calculated if any items were miss-
ing. Summaries and analysis were presented on JtD partici-
pants that had at least baseline data (n = 490), this is more 
than those randomised as a few participants withdrew prior 
to randomisation.
Both anchor-based and distribution-based methods were 
used to determine the MID as recommended by Revicki 
et al. [12]. For the anchor-based methods, the response to 
question 29 of the DEMQOL (DEMQOL Q29), which asks 
“… in the last week, how would you rate your quality of life 
overall” was considered as an anchor for DEMQOL as it is a 
self-reported single question rating of overall quality of life. 
The four responses to this item are very good, Good, Fair 
and Poor. The DEMQOL Q29 and EQ-5D were considered 
as anchors for DEMQOL-U. Spearman’s correlation coef-
ficient was calculated to assess the correlation between the 
measures and the anchors with values over 0.3 deemed as 
having acceptable association between anchor and the out-
come measure [12]. For the cross-sectional anchor analysis, 
baseline DEMQOL and DEMQOL-U were summarised over 
the four DEMQOL Q29 response categories (Quality of life 
overall: very good, good, fair and poor). One-way ANOVA 
was used to test for difference in baseline DEMQOL and 
DEMQOL-U means across the four Q29 response groups.
For the longitudinal anchor, change scores were calcu-
lated for each outcome for baseline to 8 months and baseline 
to 12 months. A change of 0.07 in EQ-5D score was used 
to classify a negative or a positive change; this was guided 
by an observed mean MID of 0.074 over 11 studies from a 
review by Walters and Brazier [9]. Participants with a less 
than 0.07 absolute change, in the EQ-5D score, were clas-
sified as no change. For the DEMQOL, change over time 
from baseline to follow-up was summarised over the seven 
possible Q29 change categories. The DEMQOL-U change 
was summarised over both Q29 and EQ-5D response catego-
ries. The negative and positive change scores were combined 
to provide a single MID estimate when the MID evidence 
was consolidated (for example, a 1 category improvement 
with the absolute values of a 1 category deterioration in 
Q29 scores) hence assuming the cohorts being combined 
are identical except for the sign.
All distribution-based methods are sample dependent (as 
they use sample SD) and are all considered as proxies to 
MID as they do not provide information about a difference 
that is considered minimally important [18]. Hence, they 
were used to provide supporting evidence of the MID and 
compared with the anchor-based MID scores. The previ-
ously observed effect size was reported, alongside SD per 
treatment group at baseline for studies that used DEMQOL. 
Studies using DEMQOL were identified through literature 
searches on Medline and EMBASE for randomised con-
trolled trials reported in English in any population type. 
Studies solely using DEMQOL-Proxy, or a translated 
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version of DEMQOL, were not included. The search also 
highlighted several observational studies using DEMQOL 
that were included in the results either due to their large 
scale or relevance.
The standardised effect size was calculated using the 
between-person SD at baseline from the JtD data for small 
(0.2 SD) to medium (0.5 SD) effect sizes [19]. Smith et al. 
[7] found the test–retest reliability (intra-class correlation) of 
DEMQOL to be 0.84 (n = 17) amongst the whole sample and 
0.76 (n = 10) amongst the subset with mild/moderate MCI 
MMSE ≥ 10. Reliability (Internal consistency—Cronbach’s 
alpha) was found to be 0.87 (n = 75) amongst the whole sam-
ple and 0.87 (n = 68) amongst those with MMSE ≥ 10. The 
standard error of measurement (SEM [20]) was calculated 
using the between-person SD at baseline and scale reliability 
(r) observed by Smith et al. [7] ( SEM = SD
√
(1 − r) ). The 
SEM was calculated using both test–retest reliability and 
Cronbach’s α.
Results
A total of 490 participants were recruited to the JtD study 
and had available baseline DEMQOL data, of these 386 also 
had 8-month data, and 344 had both baseline and 12-month 
DEMQOL data. Table 1 summarises the characteristics of 
the cohort. The median age of the cohort was 78.0 and 58% 
of the participants were male. The most prevalent diagno-
sis was Alzheimer’s (60%), the median length of time since 
dementia was diagnosed was 0.7 years (IQR 0.3–1.8 years). 
The inclusion criteria for this study were a MMSE score of 
18 or more, so all participants in the cohort had either mild 
cognitive impairment (38%) or normal cognitive function 
(62%) at baseline according to the MMSE. The characteris-
tics are presented separately for those that had baseline data, 
baseline and 8-month data, and baseline and 12-month data, 
the three groups appear to have similar characteristics, with 
a slightly lower proportion of participants with mild cogni-
tive impairment in the group with 12-month data available. 
Table 2 shows how the mean DEMQOL and DEMQOL-U 
scores changed over time for the whole cohort and the sub-
sample who completed all three assessments. Overall, there 
was little change in DEMQOL and DEMQOL-U scores over 
time.
All correlations between DEMQOL(-U) and the anchors 
at each timepoint are above the threshold of 0.3 and so the 
anchors have an appreciable association with the DEMQOL 
and DEMQOL-U (see Online Resource 2). DEMQOL-U 
has slightly higher correlation with Q29 than it does with 
EQ-5D. The correlation between change scores at 8 and 
12 months for DEMQOL-U with both EQ-5D and Q29 was 
below the threshold of 0.3; EQ-5D was particularly low 
so the longitudinal anchor analysis for DEMQOL-U and 
EQ-5D is to be treated cautiously.
Anchor‑based methods
The distributions of DEMQOL and DEMQOL-U at base-
line over the four Q29 quality of life overall categories are 
displayed in Table 3. The mean DEMQOL score is eight 
points higher in the participants that chose good health com-
pared to fair, and the difference is similar in those that chose 
very good compared to good. The difference in DEMQOL-
U between categories was around 0.06 (0.064 between fair 
and good, 0.057 between good and very good). The one-
way ANOVA for the difference in means across the four 
categories was statistically significant (p < 0.001) for both 
DEMQOL and DEMQOL-U.
The longitudinal anchor analysis is presented in Table 4. 
A one category increase in DEMQOL Q29 corresponds with 
a 7.2 average increase at 8 months and a 7.7 increase at 
12 months in DEMQOL score. The absolute difference in 
DEMQOL is smaller for a one category decrease in Q29 at 
both 8 months and 12 months (− 3.2 change at 8 months and 
− 4.3 change at 12 months). Combining the two categories 
results in an average 5.2 point absolute change at 8 months 
and 6.0 point change at 12 months. The absolute change in 
DEMQOL-U for a 1-point increase or 1-point decrease in 
Q29 ranges from 0.023 to 0.054, and DEMQOL-U change 
related to a positive or negative change in EQ-5D ranges 
from 0.007 to 0.027 in absolute value. The absolute values 
of the mild improvement and deterioration groups were com-
bined; these resulted in an average absolute change at 8 and 
12 months being 0.032 and 0.046 for the Q29 anchor and 
0.020 and 0.024 for EQ-5D anchor.
Distribution based methods
Previously observed effect size
The JtD trial compared DEMQOL outcome between the 
treatment groups at 8 or 12 months post-randomisation. 
In a review of other randomised controlled trials that used 
DEMQOL, we found 10 RCTs using DEMQOL as an out-
come: eight of these had published results [21–28] and two 
were ongoing [29, 30]. Of the eight RCTs with published 
results, one used DEMQOL as the primary outcome [27]. 
Table 5 shows that one trial observed a statistically signifi-
cant treatment difference of 7.4; however, the sample size 
was small and the standard deviations observed were not in 
line with the other studies [27]. Most of the observed stand-
ard deviations at baseline are between 12 and 15 which are 
in keeping with our observed SD of 13.1 across treatment 
groups.
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Standardised effect size
Cohen [19] defined a 0.2 standardised effect size as small 
and 0.5 as medium. Using the between-person SD at 
baseline, of 13 points, a small standardised effect size in 
DEMQOL is 2.6 points and a medium 6.5 points (Table 6).
Standard error of measurement
Using the estimates of reliability for participants with 
MMSE ≥ 10, the SEMs in Table 7 are calculated; 6.37 for 
test-retest reliability and 4.69 for internal consistency.
Table 1  Baseline characteristics for JtD participants with available data (n = 490)
Characteristic With baseline data (n = 490) With 8 m data (n = 386) With 12 m data (n = 344)
Sex
 Male 283 (57.8%) 227 (58.8%) 206 (59.9%)
 Female 207 (42.2%) 159 (41.2%) 138 (40.1%)
Age
 n (%) 490 (100.0%) 386 (100.0%) 344 (100.0%)
 Mean (SD) 77.1 (7.4) 76.4 (7.5) 76.4 (7.4)
 Median (IQR) 78.0 (73.0, 83.0) 77.0 (72.0, 82.0) 77.0 (72.0, 81.0)
 Min., Max 39.0, 93.0 39.0, 93.0 39.0, 90.0
Ethnicity
 English/Welsh/Scottish/Northern Irish/British 468 (95.5%) 368 (95.3%) 325 (94.5%)
 Irish 7 (1.4%) 5 (1.3%) 6 (1.7%)
 Any other White background 5 (1.0%) 4 (1.0%) 4 (1.2%)
 Indian 3 (0.6%) 3 (0.8%) 3 (0.9%)
 Other 6 (1.2%) 6 (1.6%) 6 (1.7%)
 Unknown 1 (0.2%) 0 (0.0%) 0 (0.0%)
Lives with others
 No 129 (26.3%) 92 (23.8%) 84 (24.4%)
 Yes 360 (73.5%) 293 (75.9%) 259 (75.3%)
Type of dementia diagnosed
 Alzheimer’s 296 (60.4%) 242 (62.7%) 216 (62.8%)
 Vascular dementia 50 (10.2%) 34 (8.8%) 29 (8.4%)
 Mixed Alzheimer’s/vascular dementia 112 (22.9%) 85 (22.0%) 77 (22.4%)
 Dementia in Parkinson disease 6 (1.2%) 5 (1.3%) 4 (1.2%)
 Frontotemporal dementia (FTD) 7 (1.4%) 6 (1.6%) 5 (1.5%)
 Lewy body dementia 4 (0.8%) 3 (0.8%) 3 (0.9%)
 Unspecified dementia 12 (2.4%) 10 (2.6%) 9 (2.6%)
 Other 2 (0.4%) 1 (0.3%) 1 (0.3%)
Length of time since dementia diagnosis (years)
 n (%) 479 (97.8%) 385 (99.7%) 343 (99.7%)
 Mean (SD) 1.3 (1.6) 1.3 (1.6) 1.4 (1.7)
 Median (IQR) 0.7 (0.3, 1.8) 0.8 (0.3, 1.8) 0.8 (0.3, 1.9)
 Min., Max 0.0, 13.0 0.0, 13.0 0.0, 13.0
MMSE cognitive impairment
 Mild 184 (37.6%) 128 (33.2%) 113 (32.8%)
 Normal 306 (62.4%) 258 (66.8%) 231 (67.2%)
MMSE (total score)
 n (%) 490 (100.0%) 386 (100.0%) 344 (100.0%)
 Mean (SD) 24.6 (3.1) 24.9 (3.1) 25.0 (3.1)
 Median (IQR) 25.0 (22.0, 27.0) 25.0 (23.0, 27.0) 25.0 (23.0, 28.0)
 Min., Max 18.0, 30.0 18.0, 30.0 18.0, 30.0
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Combining estimates
Figure 1 shows the distribution and anchor-based estimates 
of MID for both DEMQOL and DEMQOL-U. The longitudi-
nal anchor-based methods for improvement and deterioration 
are presented alongside the absolute change pooled for both 
improvement and deterioration groups. A MID of 5 is consist-
ent with the longitudinal anchor MID estimate and is centred 
amongst the distribution-based methods, it corresponds to 
a 0.38 standardised effect size. EQ-5D anchor-based meth-
ods for DEMQOL-U have been excluded from the summary 
(Fig. 1); due to the low correlation between change EQ-5D and 
DEMQOL-U change scores, the estimates will be unreliable 
and likely to underestimate MID. The DEMQOL Q29-based 
anchor methods for DEMQOL-U fall in line with 0.3–0.5 SD 
estimate range.
Discussion
We have calculated distribution, anchor, and standard 
error of measurement-based estimates of the MID for the 
DEMQOL and DEMQOL-U instruments using a large 
cohort of 490 patients with dementia. We found that the 
anchored-based estimate of the MID for the DEMQOL 
is around 5–6 points; and it is 0.02–0.05 points for the 
DEMQOL-U for comparisons between groups or within 
groups of people with dementia.
The minimum detectable change (MDC) has been defined 
as the smallest change in score (at an individual level) that 
can be detected after allowing for measurement error of 
the instrument. There are several methods for estimating 
the MDC, usually involving the standard error of measure-
ment (SEM) calculated from reliability coefficients such as 
test–retest and Chronbach’s alpha [11]. We used two meth-
ods two estimate the SEM (test–retest reliability and internal 
consistency) and calculated values of 6.4 and 4.7 for one 
SEM, respectively, from these methods.
Ideally, for a sensitive and reliable instrument, the MDC 
should be smaller than the MID [11]. The MID and MDC 
are important but they are different concepts measuring dif-
ferent things. The relationship between the MID and MDC 
is discussed by Turner et al. 2010 and de Vet (2010) [33, 34]. 
They agree that the MDC (and the associated SEM) cannot 
reliability replace the MID. They conclude that the MDC 
is a statistical property of the measurement, but the MID is 
the value of concern for interpretation and is based on the 
judgement of patients. The MDC (and the associated SEM) 
is of little relevance for interpretation [11].
We observed that the MID value from the anchor-based 
assessment of 5 was smaller than the SEM of 6.4 (based on 
test–retest reliability). In these circumstances, changes as 
large as the MID may be important for patients, but they 
cannot be distinguished from measurement error [34]. We 
also observed that the MID of 5 was slightly larger the then 
SEM of 4.7 (based on internal consistency reliability). In 
this situation, changes as large as the MID can be considered 
statistically significant and important to patients [34].
Table 2  DEMQOL and 
DEMQOL-U summaries by 
timepoint for JtD participants 
(N = 490)
DEMQOL DEMQOL-U
n Mean SD n mean SD
Participants with available data
 Baseline 490 90.7 13.0 490 0.862 0.114
 8 months 388 92.6 13.8 386 0.87 0.120
 12 months 352 92.0 14.1 345 0.872 0.117
Participants with data at all three timepoints
 Baseline 337 90.9 13.4 337 0.865 0.118
 8 months 337 92.2 14.1 337 0.868 0.124
 12 months 337 92.1 14.0 337 0.872 0.117
Table 3  DEMQOL and DEMQOL-U summaries at baseline, across 
DEMQOL Q29 categories (cross-sectional anchor)
ANOVA p < 0.001
Baseline n Mean SD 95% CI for mean
DEMQOL
Q29 Response
 Poor 10 61.6 16.1 50.5–73.2
 Fair 89 81.8 11.9 79.3–84.3
 Good 239 89.8 11.3 88.3–91.2
 Very good 152 99.2 8.3 97.9–100.5
DEMQOL-U
Q29 Response
 Poor 10 0.544 0.197 0.404–0.685
 Fair 89 0.799 0.117 0.774–0.823
 Good 239 0.863 0.092 0.851–0.875
 Very good 152 0.920 0.080 0.907–0.933
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To our knowledge, this study is the first to elicit and 
make recommendations on the MID for DEMQOL and 
DEMQOL-U. Both anchor and distribution-based methods 
were used, and results were consolidated. Anchor-based 
analysis was only conducted for anchors that achieved 
moderate correlation with the measure of choice (|r|≥ 0.3). 
Using EQ-5D as a longitudinal anchor may have over-
estimated the MID estimate of DEMQOL-U as it included 
participants with a large absolute change in the estimate—
however, the estimates that were observed were smaller than 
using DEMQOL Q29, this was likely due to the low cor-
relation between change scores, producing unreliable, and 
underestimated MID estimates.
Using global QOL as an anchor is one accepted method 
and has been used in previous studies [9, 35, 36]. The advan-
tages of using a global rating of QOL as an anchor are that 
they are relatively easy to obtain, patient-centred and can 
take into account a variety of information and determinants 
of well-being. However, in order to use an anchor-based 
method, there must exist some association (minimum cor-
relation) between the QOL items and the chosen anchor 
[12]. A potential limitation of our study is that some of the 
correlations between the anchors used in our study, and the 
DEMQOL and DEMQOL-U scores were not that strong 
(the correlations ranged from 0.38 to 0.59), with the pos-
sible result that some of the anchors may not perform well 
in defining the MID. Nonetheless, these correlations were 
above the recommended minimum thresholds of 0.30 and 
the even higher value of 0.371 recommended by Hays et al. 
[37].
Other potential limitations associated with using 
DEMQOL Q29 as an anchor include recall bias and response 
shift [11]. Response shift occurs when a patient’s views, 
values or expectations change over time. Thus, a patient’s 
health might be seen to be getting worse, yet the patient 
with dementia may assert that their QOL has not changed, 
or even that it has improved. Alternatively, a patient’s health 
status may appear to be unchanging even though that same 
patient may report substantial changes in their QOL. It is 
difficult to assess response shift in people with dementia. 
The classical way of assessing response shift is to use the 
“then test” which may not be appropriate for patients with 
dementia. The then-test usually asked patients after complet-
ing a second assessment a question such as “We would like 
you to think back to the time of your first assessment. With 
hindsight, how would you now rate the way you felt then?” 
[11]. The difference between the values of the 1st assessment 
and the then-test provides an estimate of response shift.
Recall bias occurs when the respondent’s answer to a 
question is affected by the respondent’s memory. People 
tend to forget how extreme the past was. Response is likely 
to be influenced by the patient’s status at the time of recall. 
For these reasons, items with short recall periods or items 
that ask patients to describe their current or recent status are 
preferable [11]. The DEMQOL asks respondents questions 
about how they feel “right now” or “in the last week” so 
has a short recall period. However, response shift and recall 
bias remain a possibility with people with dementia, and 
Table 4  DEMQOL and DEMQOL-U change by DEMQOL Q29 and 
EQ-5D change categories (longitudinal anchor)
*Negative change defined as ≤ 0.07, no change defined as between − 
0.07 and 0.07, positive change defined as > 0.07
n Mean SD 95% CI for mean
DEMQOL change Baseline to 8 months
 Q29 change
  − 3 3 − 22.8 18.6 − 69.1–23.5
  − 2 6 − 4.2 10.3 − 15.0–6.7
  − 1 80 − 3.2 9.6 − 5.3 to − 1.0
  0 210 1.6 9.1 0.3–2.8
  1 81 7.2 9.8 5.0–9.4
  2 7 11.4 10.6 1.6–21.3
  3 1 35.0
DEMQOL change Baseline to 12 months
 Q29 change
  − 2 12 − 8.8 10.3 − 15.3–− 2.3
  − 1 66 − 4.3 10.1 − 6.7 to  − 1.8
  0 199 1.3 9.0 0.0–2.5
  1 69 7.7 9.6 5.4–10.0
  2 3 12.7 4.0 2.6–22.7
DEMQOL− U change Baseline to 8 months
 Q29 change
  − 3 2 − 0.063 0.262 − 2.420–2.295
  − 2 6 − 0.075 0.066 − 0.145 to  − 0.006
  − 1 80 − 0.023 0.109 − 0.047–0.001
  0 209 0.002 0.114 − 0.013–0.018
  1 81 0.041 0.090 0.021–0.061
  2 7 0.078 0.071 0.012–0.144
  3 1 0.545
 EQ-5D change
  Negative* 94 − 0.007 0.106 − 0.028–0.015
  No change* 165 0.007 0.101 − 0.008–0.023
  Positive* 124 0.017 0.131 − 0.006–0.040
DEMQOL-U change Baseline to 12 months
 Q29 change
  − 2 12 − 0.045 0.085 − 0.099–0.009
  − 1 65 − 0.039 0.096 − 0.063 to  − 0.015
  0 196 − 0.005 0.093 − 0.008–0.018
  1 68 0.054 0.114 0.026–0.081
  2 3 0.139 0.102 − 0.033–0.311
 EQ-5D change
  Negative* 87 − 0.017 0.104 − 0.040–0.005
  No change* 140 0.006 0.103 − 0.011–0.023
  Positive* 113 0.027 0.096 0.009–0.045
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this is a limitation. Indeed, given our patient population, 
our study is more likely to suffer from these possible threats 
to the validity of the results than other studies using similar 
anchor-based approaches.
We used a four-point global QOL anchor which resulted 
in seven-point change scale; others have used 14 points, 
which may be more sensitive [10]. The designation of what 
response on the DEMQOL Q29 anchor which suggests 
patients as fundamentally unchanged and what response 
suggests patients have experienced a small but important 
change is inevitably subjective.
The anchor, DEMQOL Q29, did not ask the participant 
to recall their overall health but instead rate it considering 
the previous week; this is a strength of the anchor and the 
global rating of QoL. However, a limitation of the study is 
that people with dementia had to self-report their quality 
of life and be able to do so again 12 months later, in which 
time their dementia may have progressed to moderate stages, 
and therefore, self-report could be less reliable for some par-
ticipants. Only 70% (344/490) of participants completed the 
12-month assessment; some of these may have been due to 
declining health.
This study was conducted in participants with mild/mod-
erate dementia and in the relatively early stages of the dis-
ease, living in the community in the United Kingdom. Many 
(62%) of the participants were assessed as having normal 
cognitive function on the MMSE at baseline. The recom-
mended MID estimates are most applicable to studies in a 
similar patient population—a single MID is unlikely to be 
relevant for all populations, and a different MID may be 
appropriate for later-stage dementia and participants living 
in residential or nursing care. A limitation of the study is that 
21% of the participants were excluded from the longitudinal 
anchor analysis due to having missing outcome data (either 
having withdrawn from the study, lost to follow-up or death); 
however, Table 1 shows baseline characteristics to be similar 
for the subset that had available eight- and twelve-month 
data compared to all those that had baseline data.
Table 5  Standard deviation and 
observed treatment difference 
for studies using DEMQOL
a numbers separated by a comma are n at first follow-up and n at second follow-up
b DEMQOL data completion unknown, n is any outcome data
c n in cohort
Study Observed n with out-
come data (total)a




 Journeying through Dementia 381 13.0, 13.2 Not yet published
 HTA SADD  trialb [21] 456, 405 14.3, 12.8, 17.2 0.03–1.76
 The CSP-RYCT trial [22] 138 12.4, 13.4, 11.2 0.173–2.54
 SMILE study [23] 371, 343 15.5, 13.8 0.1, 0.05
 Individual cognitive stimulation 
therapy for dementia [24]
227, 264 11.76, 13.55 0.33, 1.73
 Maintenance cognitive stimula-
tion therapy [25]
218, 199 10.9, 11.7 0.3, 0.86
 The GREAT trial [26] 445, 417 12.9, 11.75 0.24, 1.08
 Crotty et al. hip fracture [27] 90,  70 27.8, 8.48 0.3–7.4
 NIHR TEAM study [28] 222 11.9, 13.4 0.7
Observational studies
 Park et al. 2017 [31] 785 12.5 n/a
 Banerjee  2006c [32] 101 13.75 n/a
Table 6  Standardised effect sizes using a baseline SD of 13 points
DEMQOL DEMQOL-U
0.2 SD 2.6 0.023
0.3 SD 3.9 0.034
0.4 SD 5.2 0.046
0.5 SD 6.5 0.057
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Second, the follow-up duration was only 12 months, 
so the MID values that were determined herein may not 
be consistent with those in studies with longer follow-up 
durations. Thus, to validate the findings of this study, a 
longer follow-up and patients with different severities of 
dementia would be needed in future studies.
Our recommended MID should be confirmed based 
on evidence from other studies, and we recommend that 
other cohorts are used to estimate MID and the evidence 
is consolidated to provide a more robust estimate. Further 
research into the MID for the DEMQOL-proxy is needed 
for people with dementia who cannot self-report.
Conclusion
In this study, we established MID scores for DEMQOL 
and DEMQOL-U using both anchor and distribution-
based methods on a prospective cohort of people living 
with dementia. We found that the anchor-based estimate 
of the MID for the DEMQOL is around 5–6 points; and 
0.02–0.05 for the DEMQOL-U. This study can guide 
researchers when designing studies and calculating sample 
sizes and when interpreting DEMQOL(-U) change over 
time and treatment differences for comparisons between 
groups or within groups of people with dementia.
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